Literature DB >> 11257012

Efficacies of gel formulations containing foscarnet, alone or combined with sodium lauryl sulfate, against establishment and reactivation of latent herpes simplex virus type 1.

J Piret1, J Lamontagne, A Désormeaux, M G Bergeron.   

Abstract

The influence of sodium lauryl sulfate (SLS) on the efficacies of gel formulations of foscarnet against herpes simplex virus type 1 (HSV-1) cutaneous lesions and on the establishment and reactivation of latent virus has been evaluated in a murine model of orofacial infection. Topical treatments were given twice daily for 3 days and were initiated at 6, 24, and 48 h after virus inoculation. The gel formulation that contained both 3% foscarnet and 5% SLS and that was administered within 48 h postinfection reduced the rate of development of herpetic skin lesions. This formulation also significantly decreased the viral content in skin tissues and in ipsilateral trigeminal ganglia when it was given within 24 and 6 h postinfection, respectively. A lower level of efficacy was observed for the gel formulation containing 3% foscarnet alone. Of prime interest, the gel formulation containing 5% SLS reduced significantly the mortality rate among mice in a zosteriform model of infection. Both formulations of foscarnet had no effect on the mean titers of reactivated virus in explant cultures of ipsilateral and contralateral trigeminal ganglia from latently infected mice. The use of a gel formulation containing combinations of foscarnet and SLS could represent an attractive approach for the treatment of herpetic mucocutaneous infections.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257012      PMCID: PMC90421          DOI: 10.1128/AAC.45.4.1030-1036.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  Host defenses in herpes simplex infections of the nervous system: effect of antibody on disease and viral spread.

Authors:  R R McKendall; T Klassen; J R Baringer
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

2.  Orofacial herpes simplex virus infection in hairless mice: latent virus in trigeminal ganglia after topical antiviral treatment.

Authors:  R J Klein; A E Friedman-Kien; P B Yellin
Journal:  Infect Immun       Date:  1978-04       Impact factor: 3.441

3.  Latent herpes simplex virus type 1 DNA contains two copies of the virion DNA joint region.

Authors:  D L Rock; N W Fraser
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

4.  Evidence that neurons harbor latent herpes simplex virus.

Authors:  M L Cook; V B Bastone; J G Stevens
Journal:  Infect Immun       Date:  1974-05       Impact factor: 3.441

5.  Latent herpes simplex virus in spinal ganglia of mice.

Authors:  J G Stevens; M L Cook
Journal:  Science       Date:  1971-08-27       Impact factor: 47.728

6.  Sodium lauryl sulfate increases the efficacy of a topical formulation of foscarnet against herpes simplex virus type 1 cutaneous lesions in mice.

Authors:  J Piret; A Désormeaux; H Cormier; J Lamontagne; P Gourde; J Juhász; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

7.  Efficacies of topical formulations of foscarnet and acyclovir and of 5-percent acyclovir ointment (Zovirax) in a murine model of cutaneous herpes simplex virus type 1 infection.

Authors:  J Piret; A Désormeaux; P Gourde; J Juhász; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

8.  Antibody-mediated recovery from subcutaneous herpes simplex virus type 2 infection.

Authors:  J E Oakes; H Rosemond-Hornbeak
Journal:  Infect Immun       Date:  1978-08       Impact factor: 3.441

9.  Effect of acycloguanosine treatment of acute and latent herpes simplex infections in mice.

Authors:  H J Field; S E Bell; G B Elion; A A Nash; P Wildy
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

10.  Neural spread of herpes simplex virus types 1 and 2 in mice after corneal or subcutaneous (footpad) inoculation.

Authors:  K Kristensson; A Vahlne; L A Persson; E Lycke
Journal:  J Neurol Sci       Date:  1978-02       Impact factor: 3.181

View more
  2 in total

1.  Pluronic F127-tailored lecithin organogel of acyclovir: preclinical evidence of antiviral activity using BALB/c murine model of cutaneous HSV-1 infection.

Authors:  Gajanand Sharma; Bimaldeep Kaur; Kanika Thakur; Akanksha Mahajan; Basant Amarji; Mini P Singh; Om Prakash Katare
Journal:  Drug Deliv Transl Res       Date:  2021-01-23       Impact factor: 4.617

2.  Novel drug delivery approaches on antiviral and antiretroviral agents.

Authors:  Pooja Sharma; Anuj Chawla; Sandeep Arora; Pravin Pawar
Journal:  J Adv Pharm Technol Res       Date:  2012-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.